These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36581779)

  • 41. Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma.
    Jiang W; Finniss S; Cazacu S; Xiang C; Brodie Z; Mikkelsen T; Poisson L; Shackelford DB; Brodie C
    Oncotarget; 2016 Aug; 7(35):56456-56470. PubMed ID: 27486821
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunotherapy targeting glioma stem cells--insights and perspectives.
    Li Z; Lee JW; Mukherjee D; Ji J; Jeswani SP; Black KL; Yu JS
    Expert Opin Biol Ther; 2012 Feb; 12(2):165-78. PubMed ID: 22200324
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma.
    Bar EE; Chaudhry A; Lin A; Fan X; Schreck K; Matsui W; Piccirillo S; Vescovi AL; DiMeco F; Olivi A; Eberhart CG
    Stem Cells; 2007 Oct; 25(10):2524-33. PubMed ID: 17628016
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
    Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
    J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lipid metabolism enzyme ACSVL3 supports glioblastoma stem cell maintenance and tumorigenicity.
    Sun P; Xia S; Lal B; Shi X; Yang KS; Watkins PA; Laterra J
    BMC Cancer; 2014 Jun; 14():401. PubMed ID: 24893952
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
    Wen PY; Touat M; Alexander BM; Mellinghoff IK; Ramkissoon S; McCluskey CS; Pelton K; Haidar S; Basu SS; Gaffey SC; Brown LE; Martinez-Ledesma JE; Wu S; Kim J; Wei W; Park MA; Huse JT; Kuhn JG; Rinne ML; Colman H; Agar NYR; Omuro AM; DeAngelis LM; Gilbert MR; de Groot JF; Cloughesy TF; Chi AS; Roberts TM; Zhao JJ; Lee EQ; Nayak L; Heath JR; Horky LL; Batchelor TT; Beroukhim R; Chang SM; Ligon AH; Dunn IF; Koul D; Young GS; Prados MD; Reardon DA; Yung WKA; Ligon KL
    J Clin Oncol; 2019 Mar; 37(9):741-750. PubMed ID: 30715997
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pterostilbene suppressed irradiation-resistant glioma stem cells by modulating GRP78/miR-205 axis.
    Huynh TT; Lin CM; Lee WH; Wu AT; Lin YK; Lin YF; Yeh CT; Wang LS
    J Nutr Biochem; 2015 May; 26(5):466-75. PubMed ID: 25736407
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regulation of Glioblastoma Tumor-Propagating Cells by the Integrin Partner Tetraspanin CD151.
    Tilghman J; Schiapparelli P; Lal B; Ying M; Quinones-Hinojosa A; Xia S; Laterra J
    Neoplasia; 2016 Mar; 18(3):185-98. PubMed ID: 26992919
    [TBL] [Abstract][Full Text] [Related]  

  • 49. E3 ubiquitin-ligase RNF138 may regulate p53 protein expression to regulate the self-renewal and tumorigenicity of glioma stem cells.
    Chao Q; Li X; Huang Y
    J Cancer Res Ther; 2023 Dec; 19(6):1636-1645. PubMed ID: 38156932
    [TBL] [Abstract][Full Text] [Related]  

  • 50. GANT-61 and GDC-0449 induce apoptosis of prostate cancer stem cells through a GLI-dependent mechanism.
    Tong W; Qiu L; Qi M; Liu J; Hu K; Lin W; Huang Y; Fu J
    J Cell Biochem; 2018 Apr; 119(4):3641-3652. PubMed ID: 29231999
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.
    Galanis E; Anderson SK; Twohy EL; Carrero XW; Dixon JG; Tran DD; Jeyapalan SA; Anderson DM; Kaufmann TJ; Feathers RW; Giannini C; Buckner JC; Anastasiadis PZ; Schiff D
    Cancer; 2019 Nov; 125(21):3790-3800. PubMed ID: 31290996
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.
    Kaley TJ; Panageas KS; Mellinghoff IK; Nolan C; Gavrilovic IT; DeAngelis LM; Abrey LE; Holland EC; Lassman AB
    J Neurooncol; 2019 Sep; 144(2):403-407. PubMed ID: 31325145
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hedgehog signaling sensitizes glioma stem cells to endogenous nano-irradiation.
    Morgenroth A; Vogg AT; Ermert K; Zlatopolskiy B; Mottaghy FM
    Oncotarget; 2014 Jul; 5(14):5483-93. PubMed ID: 24978848
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PIM1 Inhibition Affects Glioblastoma Stem Cell Behavior and Kills Glioblastoma Stem-like Cells.
    Seifert C; Balz E; Herzog S; Korolev A; Gaßmann S; Paland H; Fink MA; Grube M; Marx S; Jedlitschky G; Tzvetkov MV; Rauch BH; Schroeder HWS; Bien-Möller S
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681783
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting of glioma stem-like cells with a parthenolide derivative ACT001 through inhibition of AEBP1/PI3K/AKT signaling.
    Hou Y; Sun B; Liu W; Yu B; Shi Q; Luo F; Bai Y; Feng H
    Theranostics; 2021; 11(2):555-566. PubMed ID: 33391492
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A curcumin derivative hydrazinobenzoylcurcumin suppresses stem-like features of glioblastoma cells by targeting Ca
    Shin HJ; Lee S; Jung HJ
    J Cell Biochem; 2019 Apr; 120(4):6741-6752. PubMed ID: 30390339
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy.
    Ulasov IV; Nandi S; Dey M; Sonabend AM; Lesniak MS
    Mol Med; 2011; 17(1-2):103-12. PubMed ID: 20957337
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nanomedicines Targeting Glioma Stem Cells.
    Sabu A; Liu TI; Ng SS; Doong RA; Huang YF; Chiu HC
    ACS Appl Mater Interfaces; 2023 Jan; 15(1):158-181. PubMed ID: 35544684
    [TBL] [Abstract][Full Text] [Related]  

  • 59. FOXD1-ALDH1A3 Signaling Is a Determinant for the Self-Renewal and Tumorigenicity of Mesenchymal Glioma Stem Cells.
    Cheng P; Wang J; Waghmare I; Sartini S; Coviello V; Zhang Z; Kim SH; Mohyeldin A; Pavlyukov MS; Minata M; Valentim CL; Chhipa RR; Bhat KP; Dasgupta B; La Motta C; Kango-Singh M; Nakano I
    Cancer Res; 2016 Dec; 76(24):7219-7230. PubMed ID: 27569208
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase I/II trial of vandetanib for patients with recurrent malignant glioma.
    Kreisl TN; McNeill KA; Sul J; Iwamoto FM; Shih J; Fine HA
    Neuro Oncol; 2012 Dec; 14(12):1519-26. PubMed ID: 23099652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.